Salix completes acquisition of Santarus
01/02/2014 1:02 PM
01/02/2014 1:04 PM
Salix Pharmaceuticals announced Thursday that it has completed its $2.6 billion acquisition of the specialty drug company Santarus.
“The acquisition of Santarus is a transformational event for Salix and an important milestone in our growth as the leading gastroenterology-focused specialty pharmaceutical company in the United States,” Salix CEO Carolyn Logan said in a statement. “The creation of a larger, stronger Salix reinforces our premier position in gastroenterology and creates the opportunity for us to expand our digestive disease expertise into other key specialties.”
Raleigh-based Salix sells drugs to treat gastrointestinal ailments. Its best-selling drug, Xifaxan, is approved to treat travelers’ diarrhea and a rare liver condition. Santarus’ drugs focus on similar areas of treatment, and include Uceris, a treatment for ulcerative colitis, and the heartburn treatment Zegerid.
The deal gives Salix a portfolio of 22 drugs with annual revenue of nearly $1.35 billion.
Salix paid $32 a share for San Diego-based Santarus.
Salix shares closed Thursday at $89.09, down 85 cents. The stock is up about 25 percent since the Santarus deal was announced Nov. 7.
Staff writer David Bracken
Join the Discussion
News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.